Tyrosine kinase inhibitors
(Die Seite wurde neu angelegt: „ok some other kinases included... '''PAK-1 target''' {{tp|p=32313880|t=ä. PAK1-blockers: Potential Therapeutics against COVID-19? |pdf=|usr=}} {{tp|p=3234887…“) |
K |
||
| (3 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| − | + | {{up|PHA conventional pharmacology}} | |
| + | |||
| + | |||
| + | '''mixed retargeted oncopharmaceuticals''' | ||
| + | *'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]''' | ||
| + | {{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}} | ||
'''PAK-1 target''' | '''PAK-1 target''' | ||
| Zeile 8: | Zeile 13: | ||
'''Imatinib''' | '''Imatinib''' | ||
{{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}} | {{tp|p=32376403|t=ä. Imatinib might constitute a treatment option for lung involvement in COVID-19 |pdf=|usr=}} | ||
| − | + | {{tp|p=32599278|t=2020. Imatinib for COVID-19: A case report.|pdf=|usr=011}} | |
'''BTK Bruton Tyrosine Kinase''' ''ibrutiib'' | '''BTK Bruton Tyrosine Kinase''' ''ibrutiib'' | ||
| Zeile 14: | Zeile 19: | ||
{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}} | {{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}} | ||
{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}} | {{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}} | ||
| − | + | {{ttp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=010}} | |
'''akt PKB''' | '''akt PKB''' | ||
| Zeile 21: | Zeile 26: | ||
'''Abelson tyrosine kinase''' | '''Abelson tyrosine kinase''' | ||
{{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}} | {{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}} | ||
| − | + | {{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=009}} | |
'''p38 mapk''' | '''p38 mapk''' | ||
{{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}} | {{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}} | ||
Aktuelle Version vom 18. Januar 2021, 20:26 Uhr
| PHA conventional pharmacology |
mixed retargeted oncopharmaceuticals
| 32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |
PAK-1 target
32313880 ä. PAK1-blockers: Potential Therapeutics against COVID-19?
32348877 ä. Chemical evolution for taming the ?pathogenic kinase? PAK1
Imatinib
32376403 ä. Imatinib might constitute a treatment option for lung involvement in COVID-19
32599278 2020. Imatinib for COVID-19: A case report.
BTK Bruton Tyrosine Kinase ibrutiib
32302379 2020. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
| 32552307 2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors. |
akt PKB
32519895 2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
Abelson tyrosine kinase
32399097 2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.
32395220 2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
p38 mapk
32422320 2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
